Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
1990
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
2007 Standout
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data
1998
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
1998 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Differential Effects of Lipid-Lowering Therapies on Stroke Prevention
2003
Prevalence and Control of Diabetes in Chinese Adults
2013 Standout
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
1994
The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men
2002 Standout
Selected major risk factors and global and regional burden of disease
2002 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Coronary heart disease: seven dietary factors
1991 Standout
Antioxidants and Atherosclerotic Heart Disease
1997 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)
1991
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
1995
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000
2007 Standout
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
2002 Standout
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
1996 Standout
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
2000 Standout
Discontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?
1995
Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials
2004
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Atherosclerosis
2001 Standout
Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels
2002
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population
1995 Standout
Bias in meta-analysis detected by a simple, graphical test
1997 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Insulin in blood and insulin antibodies
1966 StandoutNobel
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
The production of experimental diabetes by means of insulin antibodies
1961
Dissecting racial bias in an algorithm used to manage the health of populations
2019 StandoutScience
THE GLUCOSE FATTY-ACID CYCLE ITS ROLE IN INSULIN SENSITIVITY AND THE METABOLIC DISTURBANCES OF DIABETES MELLITUS
1963 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions
1999
Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention
2003 Standout
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
2004 Standout
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
1998 Standout
CHRONIC PROGRESSIVE MYOPATHY WITH MYOGLOBINURIA: DEMONSTRATION OF A GLYCOGENOLYTIC DEFECT IN THE MUSCLE*
1959
The metabolism of adipose tissue in vitro
1961
Plasma insulin in health and disease
1961 StandoutNobel
MODULATION OF LIPOLYSIS IN ADIPOSE TISSUE BY FATTY ACID CONCENTRATION IN FAT CELL
1965 StandoutNobel
Prevention of Diabetes Mellitus
1965
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths
2007 Standout
Estimation of Somatomedin-C Levels in Normals and Patients with Pituitary Disease by Radioimmunoassay
1977 Standout
Iodoinsulin Used To Determine Specific Activity of Iodine-131
1966 StandoutScienceNobel
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
2016
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Metabolism of Isolated Fat Cells
1964 StandoutNobel
Crystallization and Properties of Human Muscle Phosphorylases a and b
1960 StandoutNobel
ANTIBODY-SUPPRESSIBLE AND NONSUPPRESSIBLE INSULIN-LIKE ACTIVITIES IN HUMAN SERUM AND THEIR PHYSIOLOGIC SIGNIFICANCE. AN INSULIN ASSAY WITH ADIPOSE TISSUE OF INCREASED PRECISION AND SPECIFICITY*
1963
A Platelet-Dependent Serum Factor That Stimulates the Proliferation of Arterial Smooth Muscle Cells In Vitro
1974 Standout
The partial purification from calf serum of a fraction with multiplication‐stimulating activity for chicken fibroblasts in cell culture and with non‐suppressible insulin‐like activity
1972 StandoutNobel
Cholesterol Reduction Yields Clinical Benefit
1998
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2003 Standout
Role of Adenosine 3′,5′-Monophosphate in the Effects of Insulin and Anti-insulin Serum on Liver Metabolism
1968 StandoutNobel
Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome.
1992
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Epidemiology of coronary heart disease: The Framingham study
1984
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
2002 Standout
Cholesterol Reduction Yields Clinical Benefit
1995
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Complexity and contradiction in clinical trial research
1987
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Comparative Studies on Glycogen Phosphorylase
1962 StandoutNobel
Works of Kare Gundersen being referenced
Cholesterol-lowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patients
1976
STUDIES ON THE STATE OF INSULIN IN BLOOD:THE ROLE OF GLUCOSE IN THEIN VIVODISSOCIATION OF INSULIN COMPLEXES11
1961
STUDIES ON THE STATE OF INSULIN IN BLOOD: DISSOCIATION OF PURIFIED HUMAN BLOOD INSULIN COMPLEX(ES) BY INCUBATION WITH ADIPOSE TISSUE EXTRACTSIN VITRO1
1961
Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality
1978
STUDIES ON THE STATE OF INSULIN IN BLOOD:“FREE” INSULIN AND INSULIN COMPLEXES IN HUMAN SERA AND THEIRIN VITROBIOLOGICAL PROPERTIES1
1961
Studies on the State of Insulin in Blood
1962
Studies on the State of Insulin in Blood: Materials and Methods for the Estimation of “Free” and “Bound” Insulin-Like Activity in Serum*
1962
Serum Phosphorus and Potassium Levels after Intravenous Administration of Glucose
1954